The Efficacy and Safety of Renal Denervation Combined With Pulsed Field Ablation in Preventing Recurrence of Atrial Arrhythmia in Patients With Persistent Atrial Fibrillation: An OFF-MED Trial
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 86
- 试验地点
- 1
- 主要终点
- Freedom from Atrial Arrhythmia Recurrence
研究概览
简要总结
The goal of this clinical trial is to learn whether adding renal denervation (RDN) to pulsed-field ablation (PFA) reduces recurrence of atrial tachyarrhythmias in adults (≥18 years) with persistent atrial fibrillation undergoing first-time ablation while off antiarrhythmic drugs.
The main questions it aims to answer are:
- Does PFA+RDN, compared with PFA alone, reduce the proportion of participants with any AF/atrial flutter/atrial tachycardia ≥30 seconds at 12 month?
- Is PFA+RDN safe, as measured by procedure-related serious adverse events through 30 days?
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years.
- •Patients with persistent atrial fibrillation undergoing first-time catheter ablation (defined as any episode lasting ≥7 days).
- •Symptomatic atrial fibrillation refractory to or intolerant of at least one class I or III antiarrhythmic drug and scheduled for guideline-directed catheter ablation.
- •Able to understand the study purpose, voluntarily participate, and sign the written informed consent form.
排除标准
- •Presence of advanced structural heart disease.
- •Life expectancy < 12 months.
- •Blood pressure < 90/60 mmHg.
- •Pregnant or lactating women.
- •Anatomical abnormalities of the renal arteries unsuitable for treatment as determined by pre-procedural renal CTA.
- •History of renal artery intervention, impaired renal function with estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m² (calculated by the MDRD equation).
- •Secondary atrial fibrillation due to electrolyte imbalance, thyroid disorders, or other reversible or non-cardiac causes.
- •Contraindication to pulsed-field ablation (e.g., left atrial thrombus, prior atrial septal defect occluder implantation, or permanent metallic implant in the left atrium) or to anticoagulation therapy.
- •Known inability to obtain vascular access or contraindication to femoral venous puncture.
- •Heart failure with left ventricular ejection fraction < 30% documented by transthoracic echocardiography within 3 months before ablation.
- •Patients with current or anticipated need for pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT), or prior transseptal closure with occluder device for atrial septal defect or patent foramen ovale.
研究组 & 干预措施
pulsed-field ablation alone
干预措施: Pulsed-Field Ablation (PFA) (Procedure)
renal denervation combined with pulsed-field ablation
干预措施: renal denervation (Procedure)
renal denervation combined with pulsed-field ablation
干预措施: Pulsed-Field Ablation (PFA) (Procedure)
结局指标
主要结局
Freedom from Atrial Arrhythmia Recurrence
时间窗: within 12 Months After the Index Procedure
Absence of any documented atrial tachyarrhythmia - including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds - occurring
次要结局
- Freedom from AF recurrence(within 3 months after the index procedure)
- Atrial fibrillation burden(at 3 months)
- Change in blood pressure(immediately, at 1 month, and at 3 months after procedure)
- Major adverse cardiovascular events (MACE)(up to 12 months after ablation)
研究者
Wenzheng Han
Associate Chief Physician; Administrative Deputy Director, Department of Cardiology
Shanghai Chest Hospital
